The Role of Immunotherapy in the Treatment of Asthma

Project Summary Title and Description

Title
The Role of Immunotherapy in the Treatment of Asthma
Description
To evaluate the efficacy and safety of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) in the treatment of allergic asthma
Attribution
N/A
Authors of Report
N/A
Methodology description
We searched PubMed, EmbaseĀ®, and the Cochrane Central Register of Controlled Trials (CENTRAL) from January 1,2005 through May 8, 2017. We followed the PICOTS framework in developing the criteria for inclusion of studies. Two reviewers independently screened to select randomized controlled trials (RCTs) of the efficacy of SCIT and SLIT and RCTs, observational studies, and case series or case reports on safety. Two reviewers independently assessed the risk of bias for each study and together graded the strength of the evidence.
PROSPERO
CRD42016047749
DOI
10.26300/aagy-2h07
Notes
Data was entered retrospectively (importing/uploading data in file Word format using the Manager Reports tool. There are five documents, one for each Key Question (baseline data and results) and one additional document in which all the data for risk of bias is found
Funding Source
AHRQ and NHLBI

Key Questions

1. Key Question 1. What is the evidence for the efficacy of subcutaneous immunotherapy (SCIT) in the treatment of asthma?
2. Key Question 2. What is the evidence for the safety of subcutaneous immunotherapy (SCIT) in the treatment of asthma?
3. Key Question 3. What is the evidence for the efficacy of sublingual immunotherapy (SLIT) in the treatment of asthma?
4. Key Question 4. What is the evidence for the safety of sublingual immunotherapy (SLIT) in the treatment of asthma?

Associated Extraction Forms

Associated Studies (each link opens a new tab)

TitleAuthorsYear
Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study.
Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response.
Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment.
Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma.
Assessment of short-term changes induced by a Dermatophagoides pteronyssinus extract on asthmatic patients. Randomised, double-blind, placebo-controlled trial.
A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults.1997
Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma.
Phoenix sylvestris Roxb pollen allergy: a 2-year randomized controlled trial and follow-up study of immunotherapy in patients with seasonal allergy in an agricultural area of West Bengal, India.
Ragweed immunotherapy in adult asthma.
Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses.
Immunotherapy for cat asthma.
Decrease of skin and bronchial sensitization following short-intensive scheduled immunotherapy in mite-allergic asthma.
SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma.
Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics.
A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients.
Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite.2004
Significant improvement of specific bronchial hyperreactivity in asthmatic children after 4 months of treatment with a modified extract of dermatophagoides pteronyssinus.
Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatophagoides pteronyssinus).1992
Comparison between the use of adsorbed and aqueous immunotherapy material in Dermatophagoides pteronyssinus sensitive asthmatic children.
Failure of hyposensitisation in treatment of children with grass-pollen asthma.1982
Immunotherapy in allergy to dog: a double-blind clinical study.
Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy.
Vitamin D as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust mite.
Evaluation of efficacy of immunotherapy in children with asthma monosensitized to Alternaria.-- Not Found --
Assessing the efficacy of immunotherapy with a glutaraldehyde-modified house dust mite extract in children by monitoring changes in clinical parameters and inflammatory markers in exhaled breath.
Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial.
Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study.2002
A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results.
Efficacy analysis of three-year subcutaneous SQ-standardized specific immunotherapy in house dust mite-allergic children with asthma.
Optimal duration of allergen immunotherapy in children with dust mite respiratory allergy.
A controlled trial of immunotherapy for asthma in allergic children.
Long-term immunologic effects of broad-spectrum aeroallergen immunotherapy.2006
Efficacy of immunotherapy for treatment of allergic asthma in children.
Clinical efficacy of house dust mite-specific immunotherapy in asthmatic children.
Induced apoptosis of TH2 lymphocytes in asthmatic children treated with Dermatophagoides pteronyssinus immunotherapy.2005
Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
SQ HDM SLIT-tablet (ALK) in treatment of asthma--post hoc results from a randomised trial.
Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.
SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.
House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial.
House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma.
Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
Specific immunotherapy with high dose SO standardized grass allergen tablets was safe and well tolerated.
The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: a real-life randomised trial.
Effectiveness of high dose sublingual immunotherapy to induce a stepdown of seasonal asthma: a pilot study.
Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen.2009
Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen.2010
Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study.
Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled, trial.
Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen.
Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study.
Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan.
Immunomodulation during sublingual therapy in allergic children.
Effects of sublingual immunotherapy for Dermatophagoides farinae on Th17 cells and CD4(+) CD25(+) regulatory T cells in peripheral blood of children with allergic asthma.2014
Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.2016
SQ HDM SLIT-tablet (ALK) in treatment of asthma--post hoc results from a randomised trial.2014
Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.2014
SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.2015
Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.2016
House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial.2016
House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma.2014
Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
Specific immunotherapy with high dose SO standardized grass allergen tablets was safe and well tolerated.
The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: a real-life randomised trial.
Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis.-- Not Found --
Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children.2014
Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled, trial.2007
Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.2007
Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.2009
Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen.2009
Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study.2006
Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan.2006
Immunomodulation during sublingual therapy in allergic children.2003
Safety of ultra-rush titration of sublingual immunotherapy in asthmatic children with tree-pollen allergy.2010
Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study.2001
Anaphylaxis to sublingual immunotherapy.
Severe repeated anaphylactic reactions to sublingual immunotherapy.-- Not Found --
Adverse reaction to specific immunotherapy for house-dust mite in a patient with Anisakis allergy.2008
Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose.2008
Observational study of the safety of an ultra-rush sublingual immunotherapy regimen to treat rhinitis due to house dust mites.2011
Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children's real life.2013
Sublingual immunotherapy to house dust mite in pediatric patients with allergic rhinitis and asthma: a retrospective analysis of clinical course over a 3-year follow-up period.2007
Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study.2006
Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response.2010
Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment.1985
Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma.2005
Assessment of short-term changes induced by a Dermatophagoides pteronyssinus extract on asthmatic patients. Randomised, double-blind, placebo-controlled trial.2011
Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma.1998
Decrease of skin and bronchial sensitization following short-intensive scheduled immunotherapy in mite-allergic asthma.1993
Phoenix sylvestris Roxb pollen allergy: a 2-year randomized controlled trial and follow-up study of immunotherapy in patients with seasonal allergy in an agricultural area of West Bengal, India.2006
Ragweed immunotherapy in adult asthma.1996
Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses.1984
Immunotherapy for cat asthma.1988
SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma.2011
Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics.2006
Double-blind study of tolerability and antibody production of unmodified and chemically modified allergen vaccines of Phleum pratense.2005
Significant improvement of specific bronchial hyperreactivity in asthmatic children after 4 months of treatment with a modified extract of dermatophagoides pteronyssinus.2006
Assessing the efficacy of immunotherapy with a glutaraldehyde-modified house dust mite extract in children by monitoring changes in clinical parameters and inflammatory markers in exhaled breath.2014
Vitamin D as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust mite.2014
Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial.2010
Comparison between the use of adsorbed and aqueous immunotherapy material in Dermatophagoides pteronyssinus sensitive asthmatic children.-- Not Found --
Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy.2009
Efficacy analysis of three-year subcutaneous SQ-standardized specific immunotherapy in house dust mite-allergic children with asthma.2014
A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results.1986
Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.2006
Immunotherapy in allergy to dog: a double-blind clinical study.1984
Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.2006
Optimal duration of allergen immunotherapy in children with dust mite respiratory allergy.2015
Efficacy of immunotherapy for treatment of allergic asthma in children.-- Not Found --
Clinical efficacy of house dust mite-specific immunotherapy in asthmatic children.2010
A controlled trial of immunotherapy for asthma in allergic children.1997
Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.2013
Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors.-- Not Found --
Improving the safety of immunotherapy.-- Not Found --
Allergen specific immunotherapy induced multi-organ failure.2013
Safety of accelerated schedules of subcutaneous allergen immunotherapy with house dust mite extract in patients with atopic dermatitis.2011
Vasculitis during immunotherapy treatment in a patient with allergy to Cupressus arizonica.-- Not Found --
Persistent subcutaneous nodules after immunotherapy injections for allergic asthma.2009
Specific immunotherapy improves asthma related quality of life in childhood.-- Not Found --
Safety of subcutaneous immunotherapy with inhalant allergen extracts: a single-center 30-year experience from Turkey.2015
Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice.2011
Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study.2010
Safety of rush immunotherapy using a modified schedule: a cumulative experience of 893 patients receiving multiple aeroallergens.-- Not Found --
A prospective multicenter study of systemic reactions in standardized specific immunotherapy for allergic rhinitis in China.-- Not Found --
Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study.-- Not Found --
Characterisation of systemic reactions to subcutaneous immunotherapy with airborne allergens and classification according to WAO 2010.-- Not Found --
Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood.2006

Downloadable Data Content

Files
  • XLSX Project Data